PBF-999 is under clinical development by Palo BioFarma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect PBF-999’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PBF-999 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

PBF-999 overview

PBF-999 is under development for treatment of solid tumors. The drug candidate is formulated as capsule and administered through oral route. It acts by targeting  adenosine receptor A2a (ADORA2A) and phosphodiesterase 10 (PDE10). The drug candidate was also under development for the treatment of Huntington's disease and schizophrenia.

Palo BioFarma overview

Palo BioFarma is a Spanish biotechnology company. The scientists with experience in drug discovery in several pharmaceutical companies and mission of the Palobiofarma is to discover new drugs based on the modulation of adenosine receptors. The company is headquartered Mataró, Barcelona, Spain.

Quick View PBF-999 LOA Data

Report Segments
  • Innovator
Drug Name
  • PBF-999
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.